1233354-63-6

Basic information

• Product Name: C₂₆H₂₆FNO₈S
• Synonyms: C₂₆H₂₆FNO₈S
• CAS NO: 1233354-63-6
• Molecular Weight: 531.559
• Mol File: 1233354-63-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: C₂₆H₂₆FNO₈S(CAS DataBase Reference)
• NIST Chemistry Reference: C₂₆H₂₆FNO₈S(1233354-63-6)
• EPA Substance Registry System: C₂₆H₂₆FNO₈S(1233354-63-6)

Safety Data

• Hazardous Substances Data: 1233354-63-6(Hazardous Substances Data)

Upstream product

• 29668-44-8 2,3-dihydro-benzo[1,4]dioxin-6-carbaldehyde 
• 139-85-5 3,4-dihydroxybenzaldehyde 
• 10554-64-0 2-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethan-1-amine 
• 1233354-60-3 7-methoxy-3-oxo-3,4-dihydro-1H-2-benzopyran-8-yl 3-fluorobenzene-1-sulfonate 

Downstream Products

• 1233353-88-2 11-methoxy-6,7,8,9,14,14a-hexahydro-2H,3H-1,4-dioxano[5,6-g]isoquinolino[3,2-a]isoquinolin-10-yl 3-fluorobenzenesulfonate 

Relevant articles and documents

COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING NASH, NAFLD, AND OBESITY

The present technology relates to methods of treating NASH, NAFLD and/or obesity using compounds of Formulas I, II, III, IV, V, and/or VI. The methods include administering to a subject suffering from one or more of non-alcoholic steatohepatitis (NASH), non- alcoholic fatty liver disease (NAFLD) and/or obesity a therapeutically effective amount of such a compound

CORYDALINE DERIVATIVES USEFUL FOR REDUCING LIPID LEVELS

The present technology relates to compounds of Formulas (V) and (VI) and methods of making and using such compounds. Methods of use include prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Compounds disclosed herein also lower total cholesterol, LDL- cholesterol, and triglycerides and increase hepatic LDL receptor expression, inhibit PCSK9 expression, and activate AMP-activated potein kinase.